论文部分内容阅读
目的:分析探讨急性早幼粒细胞白血病中采用化疗与三氧化二砷治疗的临床疗效。方法:选取2012年5月~2016年住院治疗的急性早幼粒细胞白血病50例患者作为研究对象,随机分为对照组(25例患者,进行化疗)和试验组(25例患者,在化疗基础上加用三氧化二砷治疗),比较两组患者治疗的有效率和不良反应发生情况。结果:试验组患者有效概率(88.00%)明显高于对照组患者有效概率(60.00%),试验组患者高血糖发生概率(48.00%)明显低于对照组患者高血糖发生概率(12.00%),统计学上有意义(P<0.05),其他不良反应如肝功能异常、胃肠道异常、维甲酸综合征等比较无统计学意义(P>0.05)。结论:急性早幼粒细胞白血病治疗中采用化疗与三氧化二砷联合的疗效显著,不良反应较少,安全性较好,明显提高患者的生存质量,值得临床大力推广使用。
Objective: To investigate the clinical efficacy of chemotherapy and arsenic trioxide in the treatment of acute promyelocytic leukemia. Methods: Fifty patients with acute promyelocytic leukemia hospitalized from May 2012 to 2016 were selected as study subjects and randomly divided into control group (25 patients, chemotherapy group) and experimental group (25 patients, based on chemotherapy Plus the use of arsenic trioxide treatment), compared two groups of patients treated with the efficiency and adverse reactions. Results: The effective rate (88.00%) in the experimental group was significantly higher than that in the control group (60.00%). The incidence of hyperglycemia in the experimental group (48.00%) was significantly lower than that in the control group (12.00%), Statistical significance (P <0.05), other adverse reactions such as liver dysfunction, gastrointestinal abnormalities, retinoic acid syndrome were no statistically significant (P> 0.05). Conclusion: The combination of chemotherapy and arsenic trioxide in the treatment of acute promyelocytic leukemia has significant curative effect, less adverse reactions, better safety, and obviously improves the quality of life of patients, which is worth to be widely promoted in clinic.